“Value-based purchasing is built on the premise that audit providers feeding them back information on their performance has been not sufficient,” says Ateev Mehrotra, MD, MPH, associate professor of healthcare policy and medicine at Harvard Medical School and a hospitalist at Beth Israel Deaconess Medical Center. In theory, if a physician were told he or she had performed poorly on a particular measure there would be a reaction and change, but he admits this is not supported by the evidence. For some reason, “audit and feedback” does not make too much of a difference with providers.
Arthur Vercillo, MD, FACS, regional president, Excellus Blue Cross Blue Shield, does not agree that providers were not influenced when presented with value-based practice data. He believes that although they initially resist changing how they practice, “When you look at the behavior later it does change.”
According to Francois de Brantes, MS, MBA, executive director of the Healthcare Incentives Improvement Institute, providing appropriate feedback to providers is now no longer a luxury but a necessity. He cites the example of a group of orthopedic surgeons who were shown their performance data as part of a value-based purchasing program—their basic takeaway was, “All those non—evidence-based things that we knew we shouldn’t do, we finally have a reason not to do.” Mr de Brantes added that many payers have driven incentives against professionalism for decades, “and they are beginning to realize that it may not be a good idea.”
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen